Odyssey Therapeutics Inc. (ODTX)
Odyssey Therapeutics Inc. (ODTX) Stock Price, Analysis & Data
| Bid | 15.22 |
| Market Cap | 1.04B |
| Revenue (ttm) | 99K |
| Net Income (ttm) | -160.03M |
| Beta | n/a |
| EPS (ttm) | -3.33 |
| PE Ratio (ttm) | n/a |
| Forward PE | -4.96 |
| P/B (ttm) | 2.46 |
| P/S (ttm) | 10489.26 |
| Earnings Date | Nov 5, 2026 |
| Ask | 27.05 |
| Volume | 62,052 |
| Avg. Volume (20D) | 308,767 |
| Open | 20.28 |
| Previous Close | 20.35 |
| Day's Range | 20.28 - 21.72 |
| 52-Week Range | 15.10 - 23.03 |
| Analyst | Strong Buy |
| Price Target | 30 (38.76%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ODTX
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of int...
Financial Performance
In 2025, Odyssey Therapeutics's revenue was 2.98M, a decrease of -33.45% compared to the previous year's 4.47M. Earnings were -148.65M, an increase of 14.94%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for ODTX stock is "Strong Buy". The 12-month stock price forecast is 30, which is upside of 38.76% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
